Ha habido 50 transacciones internas recientes registradas para Madrigal Pharmaceuticals, Inc. (MDGL), incluyendo 20 compras y 27 ventas. El total de compras internas fue valorado en $37.6M y el total de ventas internas en $8.97M.
Internos destacados con actividad reciente incluyen Taub Rebecca, Sibold William John, Dier Mardi. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — MDGL
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-06 |
Taub Rebecca |
Director |
Venta Informativa |
491 |
$431.94 |
$212.08K |
452,213 |
| 2026-03-06 |
Sibold William John |
President and CEO |
Venta Informativa |
1,663 |
$431.94 |
$718.32K |
161,829 |
| 2026-03-06 |
Dier Mardi |
EVP and CFO |
Venta Informativa |
40 |
$437.65 |
$17.51K |
12,490 |
| 2026-03-06 |
Huntsman Carole |
Chief Commercial Officer |
Venta Informativa |
419 |
$431.94 |
$180.98K |
12,692 |
| 2026-03-06 |
Kelley Shannon T |
General Counsel |
Venta Informativa |
360 |
$431.94 |
$155.5K |
12,138 |
| 2026-03-04 |
Sibold William John |
President and CEO |
Concesión de RSU |
18,743 |
$434.80 |
$8.15M |
18,743 |
| 2026-03-04 |
Dier Mardi |
EVP and CFO |
Concesión de RSU |
6,519 |
$434.80 |
$2.83M |
6,519 |
| 2026-03-04 |
Soergel David |
Chief Medical Officer |
Concesión de RSU |
5,467 |
$434.80 |
$2.38M |
5,467 |
| 2026-03-04 |
Huntsman Carole |
Chief Commercial Officer |
Concesión de RSU |
4,986 |
$434.80 |
$2.17M |
4,986 |
| 2026-03-04 |
Kelley Shannon T |
General Counsel |
Concesión de RSU |
5,022 |
$434.80 |
$2.18M |
5,022 |
| 2026-03-02 |
Dier Mardi |
EVP and CFO |
Venta Informativa |
1,183 |
$427.21 |
$505.39K |
9,257 |
| 2026-02-23 |
Levy Richard S |
Director |
Ejercicio de Opciones (Venta) |
2,500 |
$7.36 |
$18.4K |
- |
| 2026-01-26 |
Taub Rebecca |
Director |
Venta Informativa |
647 |
$492.42 |
$318.6K |
452,704 |
| 2026-01-26 |
Levy Richard S |
Director |
Ejercicio de Opciones (Venta) |
4,000 |
$16.46 |
$65.84K |
- |
| 2026-01-26 |
Sibold William John |
President and CEO |
Venta Informativa |
1,577 |
$492.42 |
$776.55K |
148,497 |
| 2026-01-26 |
Huntsman Carole |
Chief Commercial Officer |
Venta Informativa |
570 |
$494.59 |
$281.92K |
9,122 |
| 2026-01-20 |
Taub Rebecca |
Director |
Venta Informativa |
2,238 |
$490.77 |
$1.1M |
453,351 |
| 2026-01-20 |
Kelley Shannon T |
General Counsel |
Venta Informativa |
429 |
$501.40 |
$215.1K |
8,481 |
| 2026-01-15 |
Thakkar Rita |
Chief Accounting Officer |
Concesión de RSU |
1,826 |
$495.88 |
$905.48K |
1,826 |
| 2026-01-12 |
Thakkar Rita |
Officer |
Desconocido |
- |
- |
- |
- |
| 2026-01-09 |
Friedman Paul A |
Director |
Ejercicio de Opciones (Venta) |
24,520 |
$15.80 |
$387.42K |
280 |
| 2026-01-09 |
Taub Rebecca |
Director |
Venta Informativa |
271 |
$534.18 |
$144.76K |
457,242 |
| 2025-06-20 |
Bate Kenneth |
Director |
Concesión de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Friedman Paul A |
Director |
Concesión de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Baker Bros. Advisors Lp |
Director |
Concesión de RSU |
2,580 |
$285.73 |
$737.18K |
2,580 |
| 2025-06-20 |
Fouse Jacqualyn A |
Director |
Concesión de RSU |
366 |
$285.73 |
$104.58K |
366 |
| 2025-06-20 |
Levy Richard S |
Director |
Concesión de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-06-20 |
Daly James M |
Director |
Concesión de RSU |
1,290 |
$285.73 |
$368.59K |
1,290 |
| 2025-05-15 |
Soergel David |
Chief Medical Officer |
Concesión de RSU |
7,545 |
- |
- |
7,545 |
| 2025-04-21 |
Soergel David |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-03-13 |
Craves Fred B |
Director |
Ejercicio de Opciones (Venta) |
7,742 |
$65.06 |
$503.69K |
- |
| 2025-03-12 |
Craves Fred B |
Director |
Ejercicio de Opciones (Venta) |
6,000 |
$111.06 |
$666.36K |
- |
| 2025-03-10 |
Fouse Jacqualyn A |
Director |
Desconocido |
- |
- |
- |
- |
| 2025-03-10 |
Fouse Jacqualyn A |
Director |
Concesión de RSU |
894 |
- |
- |
894 |
| 2025-03-10 |
Dier Mardi |
SVP and CFO |
Venta Informativa |
258 |
$323.04 |
$83.34K |
10,440 |
| 2025-03-05 |
Taub Rebecca |
Pres., R&d, and CMO |
Concesión de RSU |
7,381 |
$347.28 |
$2.56M |
7,381 |
| 2025-03-05 |
Sibold William John |
President and CEO |
Concesión de RSU |
22,009 |
$347.28 |
$7.64M |
22,009 |
| 2025-03-05 |
Dier Mardi |
SVP and CFO |
Concesión de RSU |
6,374 |
$347.28 |
$2.21M |
6,374 |
| 2025-03-05 |
Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
Concesión de RSU |
1,157 |
$347.28 |
$401.8K |
1,157 |
| 2025-03-05 |
Huntsman Carole |
Chief Commercial Officer |
Concesión de RSU |
5,703 |
$347.28 |
$1.98M |
5,703 |
| 2025-03-05 |
Kelley Shannon T |
General Counsel |
Concesión de RSU |
5,368 |
$347.28 |
$1.86M |
5,368 |
| 2025-03-03 |
Dier Mardi |
SVP and CFO |
Venta Informativa |
774 |
$323.54 |
$250.42K |
6,914 |
| 2025-03-03 |
Huntsman Carole |
Chief Commercial Officer |
Venta Informativa |
563 |
$335.00 |
$188.61K |
8,604 |
| 2025-03-03 |
Kelley Shannon T |
General Counsel |
Venta Informativa |
415 |
$335.00 |
$139.03K |
7,290 |
| 2025-02-28 |
Waltermire Robert E. |
Senior VP, Chief Pharma Dev. |
Venta Informativa |
175 |
$341.55 |
$59.77K |
3,728 |
| 2025-02-27 |
Bate Kenneth |
Director |
Ejercicio de Opciones (Venta) |
9,470 |
$65.06 |
$616.12K |
- |
| 2025-02-27 |
Sibold William John |
President and CEO |
Ejercicio de Opciones (Venta) |
50,000 |
- |
- |
- |
| 2025-02-27 |
Daly James M |
Director |
Ejercicio de Opciones (Venta) |
9,470 |
$65.06 |
$616.12K |
- |
| 2025-01-24 |
Taub Rebecca |
Pres., R&d, and CMO |
Venta Informativa |
648 |
$335.24 |
$217.24K |
456,662 |
| 2025-01-24 |
Sibold William John |
President and CEO |
Venta Informativa |
1,584 |
$335.24 |
$531.02K |
54,303 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
